BJH: Daratumumab, lenalidomide, and dexamethasone in newly diagnosed patients with systemic light chain amyloidosis associated with multiple myeloma

Approximately 12%–15% of patients with multiple myeloma (MM) develop systemic light chain amyloidosis (AL amyloidosis) during the clinical cour.

Approximately 12%–15% of patients with multiple myeloma (MM) develop systemic light chain amyloidosis (AL amyloidosis) during the clinical cour.

According to organ involvement criteria for AL amyloidosis, 9 out of 10 patients had cardiac amyloidos.

Figure 1: Treatment response to daratumumab, lenalidomide, and dexamethasone (DRd) in newly diagnosed multiple myeloma (MM) patients with systemic AL amyloidos.

Figure 1: Treatment response to daratumumab, lenalidomide, and dexamethasone (DRd) in newly diagnosed multiple myeloma (MM) patients with systemic AL amyloidos.

At the data cutoff date (December 1, 2021), after a median follow-up of 15 months, patients had received a median of 5 cycles of D.

The presence of the t(11;14) translocation is known to be associated with low sensitivity to bortezomib in patients with AL amyloidos.

DRd causes high hematologic and cardiac responses 6 months after treatment initiation Although the patients in the cohort were relatively older and had advanced amyloidosis, most were able to continue DRd with limited toxici.

The DRd regimen may be an effective treatment option for newly diagnosed patients with systemic AL amyloidosis associated with MM who are often excluded from clinical tria.

Original source:

Original source:

Kawano,.

Kawano,.
, Hata,.
, Takashio,.
, Tsujita,.
, Ueda,.
and Matsuoka,.
(2022), Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myelom.

Br J Haemat.

https://d.

org/11111/b.

18234 Kawano,.

, Hata,.

, Takashio,.

, Tsujita,.

, Ueda,.

and Matsuoka,.

(2022) , Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myelo.

Br J Haemat.

https://d.

org/11111/b.

18234Leave a comment here